Chitosan/siRNA nanoparticles targeting cyclooxygenase type 2 attenuate unilateral ureteral obstruction-induced kidney injury in mice

Theranostics. 2015 Jan 1;5(2):110-23. doi: 10.7150/thno.9717. eCollection 2015.

Abstract

Cyclooxygenase type 2 (COX-2) plays a predominant role in the progression of kidney injury in obstructive nephropathy. The aim of this study was to test the efficacy of chitosan/small interfering RNA (siRNA) nanoparticles to knockdown COX-2 specifically in macrophages to prevent kidney injury induced by unilateral ureteral obstruction (UUO). Using optical imaging techniques and confocal microscopy, we demonstrated that chitosan/siRNA nanoparticles accumulated in macrophages in the obstructed kidney. Consistent with the imaging data, the obstructed kidney contained a higher amount of siRNA and macrophages. Chitosan-formulated siRNA against COX-2 was evaluated on RAW macrophages demonstrating reduced COX-2 expression and activity after LPS stimulation. Injection of COX-2 chitosan/siRNA nanoparticles in mice subjected to three-day UUO diminished the UUO-induced COX-2 expression. Likewise, macrophages in the obstructed kidney had reduced COX-2 immunoreactivity, and histological examination showed lesser tubular damage in COX-2 siRNA-treated UUO mice. Parenchymal inflammation, assessed by tumor necrosis factor-alpha (TNF-α) and interleukin 6 mRNA expression, was attenuated by COX-2 siRNA. Furthermore, treatment with COX-2 siRNA reduced heme oxygenase-1 and cleaved caspase-3 in UUO mice, indicating lesser oxidative stress and apoptosis. Our results demonstrate a novel strategy to prevent UUO-induced kidney damage by using chitosan/siRNA nanoparticles to knockdown COX-2 specifically in macrophages.

Keywords: Cyclooxygenase type 2; chitosan; mice.; siRNA; unilateral ureteral obstruction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury / prevention & control*
  • Animals
  • Cell Line
  • Chitosan / therapeutic use*
  • Cyclooxygenase 2 / metabolism*
  • Cyclooxygenase 2 Inhibitors / therapeutic use*
  • Disease Models, Animal
  • Histocytochemistry
  • Immunohistochemistry
  • Macrophages / enzymology
  • Male
  • Mice
  • Microscopy, Confocal
  • Nanoparticles / therapeutic use*
  • Optical Imaging
  • RNA, Small Interfering / therapeutic use*
  • Treatment Outcome
  • Ureteral Obstruction / complications*

Substances

  • Cyclooxygenase 2 Inhibitors
  • RNA, Small Interfering
  • Chitosan
  • Ptgs2 protein, mouse
  • Cyclooxygenase 2